Prochaska 2008.

Study characteristics
Methods	Study design: secondary analysis of RCT Country: USA Data collection period: April 2000 – June 2003 Registry ID: not reported
Participants	Number of participants: N = 322 Sample characteristics (at baseline): Age (mean): 42 years (SD 13); Sex (% male): 30% (97/322) Population category: psychiatric population; Specific population: people with unipolar depression Nicotine dependence: FTND 4.0 (SD 2.5); Baseline cigarettes per day: 15.5 (SD 10.1); Motivation to quit: not selected by motivation to quit, “recruitment material stated that participants did not have to want to quit smoking to participate”
Interventions	Behavioural support for smoking cessation: a computerised system that provided individualised feedback to motivate people who smoked to quit. Followed by 6 sessions of individual cognitive–behavioural counselling (motivational counselling and cessation treatment). The control group received brief cessation advice only Pharmacological support for smoking cessation: nicotine patches and possible use of bupropion (not for control group) Psychotherapeutic or psychoactive support for mental health or mood: received mood management ‐ individual cognitive‐behavioural counselling, which included mood management
Outcomes	Definition of cessation used: self‐reported 7‐day point‐prevalence abstinence Cessation definition used for outcome(s) in this analysis: point‐prevalence abstinence Measure of biovalidation: expired air carbon monoxide (≤ 10 ppm) Definition of people who continued to smoke used: people who smoked and had not reported 7‐day point‐prevalence abstinence and did not score CO ≤ 10 ppm Time point(s) at which follow‐up was conducted: baseline (before randomisation into treatment group), 3, 6, 12 and 18 months after baseline Outcome category: Depression and Psychological Quality of Life (QoL) Outcome measure(s): Beck's Depression Inventory‐II (BDI‐II); The Mental Component Summary of the Medical Outcomes Study Short Form (SF–36), days with emotional problems
Funding source	National Institute on Drug Abuse (grants K23 DA018691, K05 DA016752, and P50 DA09253) and the, State of California Tobacco‐ Related Disease Research Program (grant 13KT–0152)
Author conflicts of interest	None specified
Notes	Outcome data source: Published data